Responses
Clinical Pharmacy
CP-022 Cost-efficacy model of the introduction of emtricitabine/rilpivirine/tenofovir vs. the combination of tenofovir/emtricitabine + generic efavirenz in Spanish clinical practice
Compose a Response to This Article
Other responses
No responses have been published for this article.